APO RESEARCH · REPORT
Quetiapine Fumarate
Quetiapine Fumarate is an atypical antipsychotic drug used to treat psychiatric disorders such as schizophrenia, bipolar disorder and depression. It may be used alone or in combination with other psychiatric medications. It is taken orally, and is available only by prescription, under the supervision of a medical practitioner.
Product & engineering
Understand the product.
Quetiapine Fumarate is an atypical antipsychotic drug used to treat psychiatric disorders such as schizophrenia, bipolar disorder and depression. It may be used alone or in combination with other psychiatric medications. It is taken orally, and is available only by prescription, under the supervision of a medical practitioner.
Selected research
Industry Research
Quetiapine Fumarate Industry Research Report 2026
Market perspective
Quetiapine Fumarate is an atypical antipsychotic drug used to treat psychiatric disorders such as schizophrenia, bipolar disorder and depression. It may be used alone or in combination with other psychiatric medications. It is taken orally, and is available only by prescription, under the supervision of a medical practitioner.
Europe is the largest Quetiapine Fumarate market with about 92% market share. China is follower, accounting for about 2% market share.
The key players are AstraZeneca, Intas, TAPI, Accord, Hexal, Dr.Reddy's, Lupin, Sun Pharmaceutical, Hunan Dongting Pharm, SuZhou NO.4 Phamaceutical Factory, Fuan Pharmaceutical, Zhejiang Supor Pharmaceuticals, Zhejiang Huahai Pharmaceutical etc. Top 3 companies occupied about 74% market share.
Read the full market overview
Report Scope
This report quantifies the global Quetiapine Fumarate market in terms of revenue (US$ million) and, where applicable, sales volume (t), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/t) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Quetiapine Fumarate Market by Company
AstraZeneca
Intas
TAPI
Accord
Hexal
Dr.Reddy's
Lupin
Sun Pharmaceutical
Hunan Dongting Pharm
SuZhou NO.4 Phamaceutical Factory
Fuan Pharmaceutical
Zhejiang Supor Pharmaceuticals
Zhejiang Huahai Pharmaceutical
Quetiapine Fumarate Segment by Type
Immediate Release Tablets
Extended Release Tablets
Quetiapine Fumarate Segment by Application
Adult
Others
Quetiapine Fumarate Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Quetiapine Fumarate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Quetiapine Fumarate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Quetiapine Fumarate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Quetiapine Fumarate manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Quetiapine Fumarate by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Quetiapine Fumarate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Immediate Release Tablets
- Extended Release Tablets
Applications
- Adult
- Others
Companies covered
- AstraZeneca
- Intas
- TAPI
- Accord
- Hexal
- Dr.Reddy's
- Lupin
- Sun Pharmaceutical
- Hunan Dongting Pharm
- SuZhou NO.4 Phamaceutical Factory
- Fuan Pharmaceutical
- Zhejiang Supor Pharmaceuticals
- Zhejiang Huahai Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Quetiapine Fumarate Market Size (2021-2032)
- 2.2.2 Global Quetiapine Fumarate Sales (2021-2032)
- 2.2.3 Global Quetiapine Fumarate Market Average Price (2021-2032)
- 2.3 Quetiapine Fumarate by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Immediate Release Tablets
- 2.3.3 Extended Release Tablets
- 2.4 Quetiapine Fumarate by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adult
- 2.4.3 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Quetiapine Fumarate Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Quetiapine Fumarate Sales (t) of Manufacturers (2021-2026)
- 3.3 Global Quetiapine Fumarate Revenue of Manufacturers (2021-2026)
- 3.4 Global Quetiapine Fumarate Average Price by Manufacturers (2021-2026)
- 3.5 Global Quetiapine Fumarate Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Quetiapine Fumarate, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Quetiapine Fumarate, Product Type & Application
- 3.8 Global Manufacturers of Quetiapine Fumarate, Established Date
- 3.9 Global Quetiapine Fumarate Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AstraZeneca
- 4.1.1 AstraZeneca Company Information
- 4.1.2 AstraZeneca Business Overview
- 4.1.3 AstraZeneca Quetiapine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AstraZeneca Quetiapine Fumarate Product Portfolio
- 4.1.5 AstraZeneca Recent Developments
- 4.2 Intas
- 4.2.1 Intas Company Information
- 4.2.2 Intas Business Overview
- 4.2.3 Intas Quetiapine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Intas Quetiapine Fumarate Product Portfolio
- 4.2.5 Intas Recent Developments
- 4.3 TAPI
- 4.3.1 TAPI Company Information
- 4.3.2 TAPI Business Overview
- 4.3.3 TAPI Quetiapine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 TAPI Quetiapine Fumarate Product Portfolio
- 4.3.5 TAPI Recent Developments
- 4.4 Accord
- 4.4.1 Accord Company Information
- 4.4.2 Accord Business Overview
- 4.4.3 Accord Quetiapine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Accord Quetiapine Fumarate Product Portfolio
- 4.4.5 Accord Recent Developments
- 4.5 Hexal
- 4.5.1 Hexal Company Information
- 4.5.2 Hexal Business Overview
- 4.5.3 Hexal Quetiapine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hexal Quetiapine Fumarate Product Portfolio
- 4.5.5 Hexal Recent Developments
- 4.6 Dr.Reddy's
- 4.6.1 Dr.Reddy's Company Information
- 4.6.2 Dr.Reddy's Business Overview
- 4.6.3 Dr.Reddy's Quetiapine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Dr.Reddy's Quetiapine Fumarate Product Portfolio
- 4.6.5 Dr.Reddy's Recent Developments
- 4.7 Lupin
- 4.7.1 Lupin Company Information
- 4.7.2 Lupin Business Overview
- 4.7.3 Lupin Quetiapine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Lupin Quetiapine Fumarate Product Portfolio
- 4.7.5 Lupin Recent Developments
- 4.8 Sun Pharmaceutical
- 4.8.1 Sun Pharmaceutical Company Information
- 4.8.2 Sun Pharmaceutical Business Overview
- 4.8.3 Sun Pharmaceutical Quetiapine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sun Pharmaceutical Quetiapine Fumarate Product Portfolio
- 4.8.5 Sun Pharmaceutical Recent Developments
- 4.9 Hunan Dongting Pharm
- 4.9.1 Hunan Dongting Pharm Company Information
- 4.9.2 Hunan Dongting Pharm Business Overview
- 4.9.3 Hunan Dongting Pharm Quetiapine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Hunan Dongting Pharm Quetiapine Fumarate Product Portfolio
- 4.9.5 Hunan Dongting Pharm Recent Developments
- 4.10 SuZhou NO.4 Phamaceutical Factory
- 4.10.1 SuZhou NO.4 Phamaceutical Factory Company Information
- 4.10.2 SuZhou NO.4 Phamaceutical Factory Business Overview
- 4.10.3 SuZhou NO.4 Phamaceutical Factory Quetiapine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 SuZhou NO.4 Phamaceutical Factory Quetiapine Fumarate Product Portfolio
- 4.10.5 SuZhou NO.4 Phamaceutical Factory Recent Developments
- 4.11 Fuan Pharmaceutical
- 4.11.1 Fuan Pharmaceutical Company Information
- 4.11.2 Fuan Pharmaceutical Business Overview
- 4.11.3 Fuan Pharmaceutical Quetiapine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Fuan Pharmaceutical Quetiapine Fumarate Product Portfolio
- 4.11.5 Fuan Pharmaceutical Recent Developments
- 4.12 Zhejiang Supor Pharmaceuticals
- 4.12.1 Zhejiang Supor Pharmaceuticals Company Information
- 4.12.2 Zhejiang Supor Pharmaceuticals Business Overview
- 4.12.3 Zhejiang Supor Pharmaceuticals Quetiapine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Zhejiang Supor Pharmaceuticals Quetiapine Fumarate Product Portfolio
- 4.12.5 Zhejiang Supor Pharmaceuticals Recent Developments
- 4.13 Zhejiang Huahai Pharmaceutical
- 4.13.1 Zhejiang Huahai Pharmaceutical Company Information
- 4.13.2 Zhejiang Huahai Pharmaceutical Business Overview
- 4.13.3 Zhejiang Huahai Pharmaceutical Quetiapine Fumarate Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Zhejiang Huahai Pharmaceutical Quetiapine Fumarate Product Portfolio
- 4.13.5 Zhejiang Huahai Pharmaceutical Recent Developments
5 Global Quetiapine Fumarate Market Scenario by Region
- 5.1 Global Quetiapine Fumarate Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Quetiapine Fumarate Sales by Region: 2021-2032
- 5.2.1 Global Quetiapine Fumarate Sales by Region: 2021-2026
- 5.2.2 Global Quetiapine Fumarate Sales by Region: 2027-2032
- 5.3 Global Quetiapine Fumarate Revenue by Region: 2021-2032
- 5.3.1 Global Quetiapine Fumarate Revenue by Region: 2021-2026
- 5.3.2 Global Quetiapine Fumarate Revenue by Region: 2027-2032
- 5.4 North America Quetiapine Fumarate Market Facts & Figures by Country
- 5.4.1 North America Quetiapine Fumarate Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Quetiapine Fumarate Sales by Country (2021-2032)
- 5.4.3 North America Quetiapine Fumarate Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Quetiapine Fumarate Market Facts & Figures by Country
- 5.5.1 Europe Quetiapine Fumarate Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Quetiapine Fumarate Sales by Country (2021-2032)
- 5.5.3 Europe Quetiapine Fumarate Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Quetiapine Fumarate Market Facts & Figures by Country
- 5.6.1 Asia Pacific Quetiapine Fumarate Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Quetiapine Fumarate Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Quetiapine Fumarate Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Quetiapine Fumarate Market Facts & Figures by Country
- 5.7.1 South America Quetiapine Fumarate Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Quetiapine Fumarate Sales by Country (2021-2032)
- 5.7.3 South America Quetiapine Fumarate Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Quetiapine Fumarate Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Quetiapine Fumarate Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Quetiapine Fumarate Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Quetiapine Fumarate Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Quetiapine Fumarate Sales by Type (2021-2032)
- 6.1.1 Global Quetiapine Fumarate Sales by Type (2021-2032) & (t)
- 6.1.2 Global Quetiapine Fumarate Sales Market Share by Type (2021-2032)
- 6.2 Global Quetiapine Fumarate Revenue by Type (2021-2032)
- 6.2.1 Global Quetiapine Fumarate Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Quetiapine Fumarate Revenue Market Share by Type (2021-2032)
- 6.3 Global Quetiapine Fumarate Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Quetiapine Fumarate Sales by Application (2021-2032)
- 7.1.1 Global Quetiapine Fumarate Sales by Application (2021-2032) & (t)
- 7.1.2 Global Quetiapine Fumarate Sales Market Share by Application (2021-2032)
- 7.2 Global Quetiapine Fumarate Revenue by Application (2021-2032)
- 7.2.1 Global Quetiapine Fumarate Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Quetiapine Fumarate Revenue Market Share by Application (2021-2032)
- 7.3 Global Quetiapine Fumarate Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Quetiapine Fumarate Value Chain Analysis
- 8.1.1 Quetiapine Fumarate Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Quetiapine Fumarate Production Mode & Process
- 8.2 Quetiapine Fumarate Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Quetiapine Fumarate Distributors
- 8.2.3 Quetiapine Fumarate Customers
9 Global Quetiapine Fumarate Analyzing Market Dynamics
- 9.1 Quetiapine Fumarate Industry Trends
- 9.2 Quetiapine Fumarate Industry Drivers
- 9.3 Quetiapine Fumarate Industry Opportunities and Challenges
- 9.4 Quetiapine Fumarate Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst